Shots:

• Biogen to present data from BENEFIT study results assessing etanercept in 533 patients with rheumatoid arthritis and axial spondyloarthritis. Additionally- it presents data from pooled analyses of etanercept- infliximab and imraldi in 1-461 patients showing similarity with its reference product @6mos. & @1yr. treatment
• Biogen’s three biosimilar- Benepali (etanercept)- Flixabi (infliximab) and Imraldi (adalimumab) are expected to save $2.04B of European healthcare system in 2019. In Feb’12- Biogen & Samsung Biologics collaborates to develop & commercialize biosimilar
• Benepali (biosimilar of Enbrel)- flixabi (biosimilar of Remicade)- imraldi (biosimilar of Humira) received European Commission approval in Jan’16- May’16 and Aug’17 for multiple indication respectively

Ref: Biogen | Image: Biogen